Organisation paid for research Program year 2025 Source: CMS Open Payments

Pavel Klein

Neither a doctor nor a teaching hospital

Research payments

$482,653

30 payments

Through program year 2025, Pavel Klein is reported as receiving $482,653 in research payments, across 30 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$9,618	1
2022	Research	$16,154	1
2021	Research	$258,003	16
2020	Research	$95,824	7
2019	Research	$103,054	5

Breakdown

Who paid Research payments · program years 2019–2025

Ucb SA $265,050 12 payments
SK Life Science, Inc. $190,703 15 payments
UCB, Inc. $17,047 1 payment
AbbVie, Inc. $9,618 1 payment
UCB Biosciences Inc. $235 1 payment

Studies the money was for Research payments · program years 2019–2025

059566 $132,030 6 payments
A Multicenter, open-label study to evaluate the pharmacokinetics, Tolerability, and Safety of a Single dose of staccato alprazolam in adolescent STUDY participants with epilepsy $77,499 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy $71,591 1 payment
A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal Onset Seizures in Adult $44,351 2 payments
1-Q3ras $26,654 5 payments
Phase II/III AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPS $26,108 3 payments
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resis $22,908 1 payment
Multicenter 1 Year Observational Study of Patients Who Are Initiating Brivaracetam. $17,047 1 payment
Ykp3089c013 $16,767 2 payments
1-Fa7759 $15,252 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.